Loading…
Employees: 752
Size Autolus Therapeutics Plc Sponsored ADR (AUTL) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $341M, the 3006th largest of 3,117 United States companies the cockpit tracks. Shares closed at $1.28 on 6 Nov 2026.
Performance Over six months the shares fell 18.5%, against -21.1% for the median peer and -1.1% for the United States market (cap-weighted) — 7th highest of 20 in its peer set.
Growth Revenue grew 287.9% over the last twelve months (peer median -2.0%); the operating margin is -210.5% (peer median -24.2%).
Valuation It trades at 4.3× enterprise value to sales against a peer median of 5.0× (8th cheapest of 19).
Capital Return on invested capital runs 92.1 points below its cost of capital (10.7% WACC).
Short interest Short interest is 3.4% of the free float (15 Oct 2026).
Next results Next results expected around 10 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $117M | $75.6M | $10.1M | $1.70M | $6.19M |
| Revenue growth | — | +646% | +494% | -72% | — |
| Gross profit | $15.1M | -$21.0M | -$8.99M | -$4.89M | -$1.23M |
| EBITDA | -$236M | -$272M | -$213M | -$189M | -$160M |
| Net income | -$279M | -$288M | -$221M | -$209M | -$149M |
| Free cash flow | -$232M | -$303M | -$228M | -$157M | -$123M |
| Capital expenditure | $15.1M | $27.2M | $34.8M | $11.0M | $10.8M |
| Total debt | $368M | $352M | $297M | $224M | $150M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | AUTL | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -27.7% | -9.1% | 2nd lowest of 20 |
| 6-month return | -18.5% | -21.1% | 7th highest of 20 |
| Distance from 52-week high | -50.4% | -33.5% | 4th lowest of 20 |
| Revenue growth (TTM) | +287.9% | -2.0% | highest of 19 |
| Operating margin | -210.5% | -24.2% | 4th lowest of 19 |
| EV / Sales | 4.3× | 5.0× | 8th cheapest of 19 |
| ROIC minus cost of capital | -92.1 pp | -11.6 pp | lowest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Autolus Therapeutics Plc Sponsored ADR AUTL | United States | $341M | -18% | +288% | -211% | 4.3× | n/a | n/a |
| ASKA Pharmaceutical 4886.T | Japan | $342M | -31% | +11% | n/a | n/a | n/a | n/a |
| BioDlink International 1875.HK | Hong Kong | $342M | -29% | -51% | -31% | 4.9× | n/a | n/a |
| Foresee Pharmaceuticals 6576.TWO | Taiwan | $343M | -9% | +6% | -104% | 22.9× | n/a | n/a |
| Atea Pharmaceuticals AVIR | United States | $346M | -21% | n/a | n/a | n/a | n/a | n/a |
| Opus Genetics IRD | United States | $348M | -19% | -36% | -513% | 29.9× | n/a | n/a |
| Zhejiang East Asia Pharmaceutical 605177.SS | China | $348M | -3% | +3% | -17% | 3.1× | n/a | n/a |
| Chengdu Huasun Technology 000790.SZ | China | $333M | -22% | -36% | -57% | 5.9× | 28.5% | -6.4% |
| Pharmicell 005690.KS | South Korea | $352M | -56% | +51% | 32% | 3.2× | -6.6% | +24.8% |
| Honz Pharmaceutical 300086.SZ | China | $330M | -35% | -23% | -54% | 7.9× | 58.0% | -12.8% |
| Standard Chemical & Pharmaceutical 1720.TW | Taiwan | $329M | 0% | +3% | 21% | 1.8× | -10.4% | +10.3% |
| Beihai Gofar Chuanshan Biological 600538.SS | China | $328M | -38% | +10% | -8% | 6.2× | n/a | n/a |
| Hangzhou Tianmushan Pharmaceutical Enterprise 600671.SS | China | $327M | -10% | -19% | 5% | 11.5× | 22.5% | +0.5% |
| Enwei Pharmaceutical 301331.SZ | China | $326M | -20% | -7% | 5% | 2.3× | 15.1% | +7.3% |
| Lumosa Therapeutics 6535.TWO | Taiwan | $356M | -49% | -8% | -883% | 324.5× | n/a | n/a |
| Solara Active Pharma Sciences SOLARA.NS | India | $323M | +23% | +27% | 8% | 2.3× | 37.7% | -3.2% |
| Hainan Huluwa Pharmaceutical 605199.SS | China | $322M | -21% | -32% | -58% | 5.0× | 2.5% | -4.9% |
| 6467 6467.TW | Taiwan | $322M | n/a | n/a | -2,618% | 1,229.5× | n/a | n/a |
| Ind-Swift Laboratories INDSWFTLAB.NS | India | $321M | +149% | +66% | 9% | 3.5× | n/a | n/a |
| KYORIN Pharmaceutical 4569.T | Japan | $362M | -30% | -5% | 2% | 0.5× | 10.5% | +4.2% |
| Enanta Pharmaceuticals ENTA | United States | $320M | -28% | +1% | -90% | 4.8× | n/a | n/a |